Last reviewed · How we verify
A Randomized, Double-Blind, Placebo-Controlled, 4-week Study to Evaluate the Safety and Efficacy of T0903131 Besylate in Subjects With Type 2 Diabetes Mellitus
The purpose of the study is to determine if repeated daily doses of T0903131 (INT131) Besylate over 4 weeks can lower fasting blood glucose in patients with Type 2 Diabetes Mellitus.
Details
| Lead sponsor | InteKrin Therapeutics, Inc. |
|---|---|
| Phase | Phase 2 |
| Status | COMPLETED |
| Enrolment | 70 |
| Start date | 2003-12 |
| Completion | 2004-06 |
Conditions
- Diabetes Mellitus, Type II
Interventions
- T0903131 Besylate
- Placebo
Countries
United States